Gains of 20q11.21 in human pluripotent stem cells: Insights from cancer research.
Stem Cell Reports
; 19(1): 11-27, 2024 01 09.
Article
en En
| MEDLINE
| ID: mdl-38157850
ABSTRACT
The genetic abnormalities observed in hPSC cultures worldwide have been suggested to pose an important hurdle in their safe use in regenerative medicine due to the possibility of oncogenic transformation by mutant cells in the patient posttransplantation. One of the best-characterized genetic lesions in hPSCs is the gain of 20q11.21, found in 20% of hPSC lines worldwide, and strikingly, also amplified in 20% of human cancers. In this review, we have curated the existing knowledge on the incidence of this mutation in hPSCs and cancer, explored the significance of chromosome 20q11.21 amplification in cancer progression, and reviewed the oncogenic role of the genes in the smallest common region of gain, to shed light on the significance of this mutation in hPSC-based cell therapy. Lastly, we discuss the state-of-the-art strategies devised to detect aneuploidies in hPSC cultures, avoid genetic changes in vitro cultures of hPSCs, and strategies to eliminate genetically abnormal cells from culture.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Madre Pluripotentes
Límite:
Humans
Idioma:
En
Revista:
Stem Cell Reports
Año:
2024
Tipo del documento:
Article
País de afiliación:
Bélgica
Pais de publicación:
Estados Unidos